ULTI.OL

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$57M	+171.4%	$0.25	$0.25–$0.25	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
ULTI.OLUltimovacs ASA	$2.05	+0.00%	$71M	—
BGBIO.OLBerGenBio ASA	$1.17	+0.00%	$46M	—
NANOV.OLNordic Nanovector ASA	$1.93	-3.30%	$451M	—
NYKD.OLNykode Therapeutics AS	$3.92	+3.02%	$1.3B	—
PCIB.OLPCI Biotech Holding ASA	$0.07	+0.00%	$3M	—
TRVX.OLTargovax ASA	$0.59	+0.00%	$123M	—

Source: Financial Modeling Prep · peers by sector/industry

Ultimovacs ASA

Ultimovacs ASA is a pharmaceutical company based in Oslo, Norway, established in 2011. The firm specializes in developing immunotherapies to combat various cancers. Its main product in development is UV1, a peptide vaccine engineered to stimulate a T-cell immune response against telomerase, an antigen found widely across different cancer types.

ultimovacs.com

Employees: 12
IPO / List date: Jun 3, 2019
HQ: NO

Held by traders on TradeandTell

No one on the platform currently holds ULTI.OL.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in ULTI.OL as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded ULTI.OL yet.